alexa Clinical impact of checkpoint inhibitors as novel cancer therapies.
Biochemistry

Biochemistry

Biochemistry & Analytical Biochemistry

Author(s): Shih K, Arkenau HT, Infante JR

Abstract Share this page

Abstract Immune responses are tightly regulated via signaling through numerous co-stimulatory and co-inhibitory molecules. Exploitation of these immune checkpoint pathways is one of the mechanisms by which tumors evade and/or escape the immune system. A growing understanding of the biology of immune checkpoints and tumor immunology has led to the development of monoclonal antibodies designed to target co-stimulatory and co-inhibitory molecules in order to re-engage the immune system and restore antitumor immune responses. Anti-cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) antibodies were among the first to be tested in the clinic, and ipilimumab was the first immune checkpoint inhibitor approved for an anticancer indication. Agents targeting the programmed death 1 (PD-1) pathway, either PD-1 or one of its ligands, programmed death ligand 1, are in active clinical development for numerous cancers, including advanced melanoma and lung cancer. Understanding the different mechanisms of action, safety profiles, and response patterns associated with inhibition of the CTLA-4 and PD-1 pathways may improve patient management as these therapies are moved in to the clinical practice setting and may also provide a rationale for combination therapy with different inhibitors. Additional immune checkpoint molecules with therapeutic potential, including lymphocyte activation gene-3 and glucocorticoid-induced tumor necrosis factor receptor-related gene, also have inhibitors in early stages of clinical development. Clinical responses and safety data reported to date on immune checkpoint inhibitors suggest these agents may have the potential to markedly improve outcomes for patients with cancer.
This article was published in Drugs and referenced in Biochemistry & Analytical Biochemistry

Relevant Expert PPTs

Relevant Speaker PPTs

  • Bozena Futoma-Koloch
    C3 component deposition on Salmonella O48 cells characterized by sialylated lipopolysaccharide and different pattern of outer membrane proteins
    PPT Version | PDF Version
  • Sumru Savas
    No relationship between lipoprotein-associated phospholipase A2, proinflammatory cytokines, and neopterin   in Alzheimer's disease
    PPT Version | PDF Version
  • Mapitsi S Thantsha
    In vitro antagonistic effects of Listeria adhesion protein (LAP)-expressing Lactobacillus casei against Listeria monocytogenes and Salmonella Typhimurium Copenhagen
    PPT Version | PDF Version
  • Tibor Tot
    Multiparameter characterization of breast carcinoma: subgross, microscopy, proteins, and genes
    PPT Version | PDF Version
  • Monray Edward Williams
    Molecular validation of putative antimicrobial peptides for improved Human Immunodeficiency Virus diagnostics via HIV protein p24
    PPT Version | PDF Version
  • Kuna Yellamma
    Kuna-Yellamma-Sri-Venkateswara-University-India-Evaluation-of-neuroprotective-effect-of-silk-protein
    PPT Version | PDF Version
  • Yosef Yarden
    Classically, the 3’untranslated region (3’UTR) is that region in eukaryotic protein-coding genes from the translation termination codon to the polyA signal. It is transcribed as an integral part of the mRNA encoded by the gene. However, there exists another kind of RNA, which consists of the 3’UTR alone, without all other elements in mRNA such as 5’UTR and coding region. The importance of independent 3’UTR RNA (referred as I3’UTR) was prompted by results of artificially introducing such RNA species into malignant mammalian cells. Since 1991, we found that the middle part of the 3’UTR of the human nuclear factor for interleukin-6 (NF-IL6) or C/EBP gene exerted tumor suppression effect in vivo. Our subsequent studies showed that transfection of C/EBP 3’UTR led to down-regulation of several genes favorable for malignancy and to up-regulation of some genes favorable for phenotypic reversion. Also, it was shown that the sequences near the termini of the C/EBP 3’UTR were important for its tumor suppression activity. Then, the C/EBP 3’UTR was found to directly inhibit the phosphorylation activity of protein kinase CPKC in SMMC-7721, a hepatocarcinoma cell line. Recently, an AU-rich region in the C/EBP 3’UTR was found also to be responsible for its tumor suppression. Recently we have also found evidence that the independent C/EBP 3’UTR RNA is actually exists in human tissues, such as fetal liver and heart, pregnant uterus, senescent fibroblasts etc. Through 1990’s to 2000’s, world scientists found several 3’UTR RNAs that functioned as artificial independent RNAs in cancer cells and resulted in tumor suppression. Interestingly, majority of genes for these RNAs have promoter-like structures in their 3’UTR regions, although the existence of their transcribed products as independent 3’UTR RNAs is still to be confirmed. Our studies indicate that the independent 3’UTR RNA is a novel non-coding RNA species whose function should be the regulation not of the expression of their original mRNA, but of some essential life activities of the cell as a whole.
    PPT Version | PDF Version
  • Shigeomi Horito
    Reconstruction of a transmembrane protein tetraspanin (CD9) into lipid bilayer by interaction of ganglioside GM3 and tetraspanin
    PPT Version | PDF Version
  • Maria A. Miteva
    In silico screening to discover inhibitors of protein-protein interactions targeting angiogenesis
    PPT Version | PDF Version
  • Konrad Sandhoff
    Lysosomal & extracellular degradation of GlcCer: Protein & lipid modifiers
    PPT Version | PDF Version
  • David Ben-Menahem
    O-glycosylation and protein evolution: the case of the LHb to CGb development
    PPT Version | PDF Version
  • Vladimir Sulimov
    “Vladimir Sulimov-Dimonta-Ltd-and-Lomonosov-Moscow-State-University-Russia-Protein-ligand-low-energy-minima-pose-analysis-Docking-target-functions-evaluation-with-the-FLM-program”
    PPT Version | PDF Version
  • Xingmin Sun
    A chimeric protein (mTcd138) comprising the glucosyltransferase and domains of toxin B and the receptor binding domain of toxin A provides full protection against Clostridium difficile infection in mice
    PPT Version | PDF Version
  • Simon J Clark
    The role of complement factor H-like and factor H-related proteins in age-related macular degeneration
    PPT Version | PDF Version
  • Rivan Sidaly
    Hypoxia increases the expression of enamel proteins and cytokines in an ameloblast-derived cell line
    PPT Version | PDF Version

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords